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Visceral leishmaniasis is one of the most important sever diseases in tropical and subtropical countries. In the present study the
eﬀects of antimony sulfide nanoparticles on Leishmania infantum in vitro were evaluated. Antimony sulfide NPs (Sb2S5) were
synthesized by biological method from Serratia marcescens bacteria. Then the cytotoxicity eﬀects of diﬀerent concentrations (5, 10,
25, 50, and 100 μg/mL) of this nanoparticle were assessed on promastigote and amastigote stages of L. infantum. MTT method was
used for verification results of promastigote assay. Finally, the percentages of apoptotic, necrotic, and viable cells were determined
by flow cytometry. The results indicated the positive eﬀectiveness of antimony sulfide NPs on proliferation of promastigote form.
The IC50 (50% inhibitory concentration) of antimony sulfide NPs on promastigotes was calculated 50 μg/mL. The cytotoxicity
eﬀect was dose-dependent means by increasing the concentration of antimony sulfide NPs, the cytotoxicity curve was raised and
the viability curve of the parasite dropped simultaneously. Moreover, the IC50 of antimony sulfide NPs on amastigote stage was
calculated 25 μg/mL. On the other hand, however, antimony sulfide NPs have a low cytotoxicity eﬀect on uninfected macrophages
but it can induce apoptosis in promastigote stage at 3 of 4 concentrations.
1. Introduction
Leishmaniasis is considered as one of the most important
tropical diseases with worldwide distribution [1]. The disease
is reported in 88 countries around the world, and its preva-
lence is estimated to be approximately 12 million annually
and about 350 million people are at the risk of the disease [1,
2]. About 90% of cases of cutaneous leishmaniasis are found
in Brazil, Afghanistan, Iran, Peru, Saudi Arabia, and Syria,
and about 90% cases of visceral leishmaniasis are reported in
Bangladesh, Brazil, Nepal, India, and Sudan [3, 4]. Visceral
leishmaniasis (Kala-azar) is characterized by the presence
of fever, splenomegaly, hepatomegaly, swollen lymph nodes,
and weight loss that depends on the pathogenicity of
Leishmania species and the host immune response against
parasite [5, 6]. About 90% of the cases of this disease may
lead to death if it is left without any treatment. Leishmaniasis
coinfection with HIV and other immunosuppression is
becoming another serious problem, therefore the treatment
methods mostly focus on induction of immune responses
[5]. Pentavalent antimonials are a group of compounds
used for the treatment of leishmaniasis. The compounds
currently available for clinical use are sodium stibogluconate
(Pentostam) and meglumine antimonate (Glucantime). In
systemic therapy of leishmaniasis these drugs are used alone
or in combination with other compounds [7–15]. The
current drugs is not so much suitable due to resistance
reported, high toxicity, various side eﬀects and so forth.
So, new therapeutic antileishmanial strategies are urgently
required [5, 16].
Nanomedicine is the medical application of nanotech-
nology. Nanomedical approaches to drug delivery center
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on developing nanoscale particles [17]. Up to now vari-
ous nanoparticle compounds have been introduced against
leishmaniasis [18–27]. In the present study we evaluated
the eﬀects of antimony sulfide nanoparticles on Leishmania
infantum in vitro.
2. Materials and Methods
2.1. Drug Preparation. Antimony sulfide nanoparticle was
synthesized by intracellular biological methods from nonpig-
mented by using of the Serratia marcescens bacterial isolate
from the Caspian Sea in northern of Iran with the size
less than 35 nm according to Bahrami et al. [28] in the
Department of Pharmaceutical Biotechnology and Phar-
maceutical Sciences Research Centre, Faculty of Pharmacy,
Tehran University of medical sciences.
2.2. Parasites. Leishmania infantum MON-1 (MHOM/TN/
80/IPT1) was provided from Pasteur Institute of Iran.
Promastigotes were cultured in RPMI1640 medium supple-
mented with 10% fetal calf serum (FCS) and antibiotics
(100 IU/mL of penicillin and 100 μg/mL of streptomycin).
The culture was maintained in 24◦C for promastigote
proliferation. The parasites were transferred weekly from
previous culture into new medium.
2.3. Drug Assessment. The interaction of antimony sulfide
NPs directly and promastigotes was studied. After pro-
liferation of the parasites, 100 μL of promastigotes (2 ×
106 cell/mL) was seeded in 24-well plate containing 100 μL
of RPMI1640 medium and treated with serial dilutions of
the antimony sulfide NPs (5, 10, 25, 50, and 100 μg/mL) for
24, 48, and 72 hours. After incubation, the antileishmanial
activity of antimony sulfide NPs was evaluated by direct
counting of parasites. These data were analyzed by Graph pad
Prism version 5.04 software.
2.4. MTT Test. Briefly, 100 μL of promastigotes (2 ×
106 cells/mL) was cultured separately in 96-well microplates
containing 100 μL of RPMI1640 medium supplemented with
20% FCS. These cultures were repeated at least three times
in triplicate wells. 200 μl of promastigotes were cultured
as control group. 200 μL/well PBS was added around well
of plates to prevent the evaporation of well contents. The
cells were incubated in presence seven dilutions of antimony
sulfide NPs at 24± 1◦C for 72 hours and then 20 μL of MTT
solution was added into each of wells. Plates were incubated
again at 24◦C for 4 hours and then centrifuged at 1000 g for
10 minutes. Supernatant was aspirated gently and discarded.
100 μL DMSO was added to each of the wells and finally the
absorbance of these plates was measured by the ELISA reader
system in at 540 nm.
2.5. Macrophage Cytotoxicity Measurement. Inbred male
BALB/c mice were prepared from Razi Institute of Iran. The
eﬀect of antimony sulfide NPs on macrophages of infected
and uninfected mice was evaluated. In this regard, 7mL of
RPMI medium (sigma) was injected into peritoneumand
macrophages were collected. Then the number of live
macrophages was counted. 100 μL of macrophages with
100 μL RPMI1640 medium were seeded in exposure to
seven dilutions of antimony sulfide NPs. These cultures were
maintained at 37◦C in the presence of 5%CO2 for 24, 48, and
72 hours. The experiment was terminated by direct counting.
Cytotoxic eﬀect of antimony sulfide NPs on macrophage was
evaluated and compared with control cultures.
2.6. Intracellular Amastigote Assay. Peritoneal cavity ma-
crophages of BALB/c were seeded in 24-well plates and
incubated at 37◦C with 5%CO2 for 24 hours for diﬀer-
entiation. The cells were infected with promastigotes of
stationary growth phase at a parasite/macrophage ratio of
10 : 1. Drug susceptibilities of intracellular amastigotes were
assessed with the method previously described by Tada et al.
[29]. The culture was incubated at 37◦C in the presence of
5% CO2 for 24 hours until promastigotes were phagocyte
by macrophages. After incubation, each well of the plates
was washed with 1-2mL PBS to remove the extracellular
promastigotes. Then infected macrophages were separated
from the plates by cold method (10–15 minutes on ice
pieces). Then 5 μL of these cells were stained by Giemsa
method. The percentage of infected cells and the number
of amastigotes in each cell was microscopically assessed.
After that 100 μL of these cells were transferred into new
plate and were incubated with seven dilutions of antimony
sulfide NPs at 37◦C with 5% CO2 for 24, 48, and 72 hours.
Finally, the plates were incubated on ice pieces for 10–15
minutes. The percentage of infection and IC50 was calculated
through examination of 200 macrophages and the number
of amastigotes in every single cell. The results were expressed
as the infection index, which is reflecting of drug eﬀect in
prevention of infection.
2.7. Promastigote Apoptosis Assessment. At first 2 ×
106 cells/ml of promastigotes were treated with various
dilutions (10, 25, 50, 100 μg/mL) of antimony sulfide NPs in
ELISA plates and incubated at 24◦C for 72 hours. Test and
control wells were washed twice by cold PBS solution and
centrifuged in 1400 rpm for 10min. 100 μL Annexin-V FITC
solution and 100 μL PI (propidium iodide) solution were
added and incubated for 15 minutes at room temperature.
Subsequently, cellular apoptosis in our study was detected
by using Annexin-V FLUOS staining kit (Roche, Germany).
The procedure was performed according to manufacturing
protocol in the dark place and was evaluated FACSCalibur
system. Afterwards the flow cytometry results were then
analyzed using CellQuest software.
3. Statistical Analysis
The results of test and control groups were analyzed and
compared by ANOVA statistical test (P ≤ 0.05) using SPSS
version 15 software and Graph pad prism version 5.04.















































Figure 1: Viability of test and control groups of promastigote of L.
infantum in 5 dilutions of antimony sulfide NPs during 24, 48, and
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Figure 2: Percentage of viability of promastigotes of Leishmania
infantum and cytotoxicity of 5 dilutions of antimony sulfide NPs
at 72 hours by MTT method.
4. Results
The results indicated the positive eﬀectiveness of antimony
sulfide NPs on proliferation of promastigote form. The
cytotoxic eﬀect of 5 dilutions of antimony sulfide NPs
on promastigotes was assessed and compared with control
group in Figure 1. The IC50 (50% inhibitory concentration)
















































Figure 3: Viability of uninfected mouse macrophages in 5 dilutions

















































Figure 4: Viability of mouse macrophages contained amastigotes of
Leishmania infantum in 5 dilutions of antimony sulfide NPs in vitro
conditions during 24, 48, and 72 hours of incubation.
MTT method was used for verification results of pro-
mastigote assay. Cytotoxicity of diﬀerent concentration of
the drug and viability of promastigote stage of the parasite
are shown in Figure 2. By increasing the concentration of
antimony sulfide NPs, the cytotoxicity curve raised and the
viability curve of the parasite dropped simultaneously.
Cytotoxic eﬀect of 5 dilutions of antimony sulfide NPs
on uninfected splenic macrophages of BALB/c mice was











































































Figure 5: Induction of apoptosis in promastigotes of Leishmania infantum evaluated by flow cytometry method. (a) Most of promastigotes
were alive and healthy (control group), (b) under 10 μg/mL of antimony sulfide NPs, (c) under 25 μg/mL of antimony sulfide NPs, (d) under
50 μg/mL of antimony sulfide NPs, and (e) under 100 μg/mL of antimony sulfide NPs.
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compared with control cultures at 24, 48, 72 hours. The result
as is shown in Figure 3, indicated that antimony sulfide NPs
has low cytotoxicity eﬀect on uninfected macrophages.
The viability of mouse macrophages contained amastig-
otes of Leishmania infantum in 5 dilutions of antimony
sulfide NPs in vitro conditions during 24, 48, and 72 hours
of incubation is shown in Figure 4. Moreover, the IC50 of
antimony sulfide NPs on amastigote stage of L. infantum was
calculated 25 μg/mL.
The percentages of apoptotic, necrotic, and viable cells
were determined by flow cytometry. The basis of 4 areas
are the cells staining with Annexin-V only as apoptotic cells
(lower right region), the cells staining with PI as necrotic cells
(upper left region), the cells staining with both of Annexin-
V and PI as late apoptotic (upper right region), and those
cells that did not stain as healthy cells (lower left region).
The result indicated that antimony sulfide NPs can induce
apoptosis in promastigote stage of Leishmania at 3 of 4
concentrations (Figure 5).
5. Discussion
Pentavalent antimonials including meglumine antimoniate
(Glucantime) and stibogluconate sodium (Pentostam) are
considered the drugs of choice for treatment of all clinical
forms of leishmaniasis, for 40 years [30–36]. Despite some
limitations attributed to its use due to resistance reported,
high toxicity, various side eﬀects and the high cost, they still
remain the most important drugs against leishmaniasis. So,
the need for new eﬀective drugs with low toxicity and more
eﬀectiveness is critical.
Nanotechnology can be a useful tool for synthesize
new drugs against infectious diseases. Nanoparticles like
emulsomes, liposomes, and nanospheres have been of great
importance for drug delivery as drug carriers [37]. Among
several nanoparticles implementing for treatment, liposomes
are the best for evaluating the eﬃcacy of antileishmanial
activity of drugs as compared to any other parasitic disease
mainly due to the fact that Leishmania parasite resides within
the macrophages which are responsible for clearance of
liposomes in vivo [38]. Liposomal formulation with drug has
been proved to be successful against leishmaniasis. Moreover,
the use of conventional liposomes with antileishmanial drugs
has been proved to be associated with the reduction in their
toxicity profile [37].
In fact macrophage surface contains receptors that
recognize terminal galactose, mannose, fucose, or glucose
residues of glycosides therefore sugar bearing liposomes
were designed for improvement in macrophage targeting of
antileishmanial agents [39]. In addition, mannose-grafted
liposomal form was more eﬃcient in transporting the
drug to macrophages [40]. Furthermore, macrophages upon
interaction with particulate drug delivery vehicles may act
as secondary drug repository and contribute in localized
delivery of the drug at the infected site [39].
In addition, polymeric particles like synthetic aliphatic
polyesters (polylactic acid) PLA, polyglycolic acid, and their
copolymers (PLGA, or polycaprolactone) are the primary
candidates for the development of nanoparticle-based deliv-
ery system. They oﬀer several advantages as compared with
liposomes: high drug-loading capacity, long-term stability,
and suitability for oral administration. Moreover, they can
control the drug release. When prepared with biodegradable
and biocompatible polymers, they are welltolerated [41].
They may consist of either a polymeric matrix (nano- or
microspheres) or of a reservoir system (nano- or microcap-
sules).
In this regard, Venier-Julienne et al. used PLGA-NP
for delivery of amphotericin B against L. donovaniin vitro
[18]. The activity of pentamidine loaded poly (D, L-lactide)
nanoparticles against L. infantum in a murine model has
been investigated by Durand et al. [19]. The activity and
ultrastructural localization of primaquine-loaded poly (D,
L-lactide) nanoparticles in L. donovani infected mice has
been conducted by Rodrigues et al. [20]. The antileish-
manial activities of 2′,6′-dihydroxy-4′-methoxychalcone by
entrapment in poly(D,L-lactide) nanoparticles has been
investigated by Torres-Santos et al. [21]. Durand et al.
studied the activity of pentamidine loaded methacrylate
nanoparticles against L. infantum in a mouse model [22].
Gaspar et al. studied in vitro activity of primaquine-loaded
poly(alkyl cyanoacrylate) nanoparticles against intracellular
L. donovani [23]. Espuelas et al. studied in vitro antileish-
manial activity of amphotericin B loaded in poly(epsilon-
caprolactone) nanospheres [24].
These nanoparticles in this study were prepared in the
Department of Pharmaceutical Biotechnology and Phar-
maceutical Sciences Research Centre, Faculty of Pharmacy,
Tehran University of medical sciences. The antimony NPs
in our study were composed of sulfur and antimony atoms
at ratio of 84/16 and these particles were as Sb2S5 in their
cytoplasm or other internal bacterial spaces according to
Bahrami et al. Other characteristics of antimony sulfide NPs
in this study and its green synthetic method are present
in Bahrami et al. literature [28]. In our study, instead of
using any additional compound for delivery of antimony
sulfide, nanoparticle form of the drug was synthesized and
its eﬀects on Leishmania infantum in vitro condition were
evaluated. Our results indicated the positive eﬀectiveness of
antimony sulfide NPs on proliferation of promastigote form.
In addition, the drug can induce apoptosis in promastigotes.
So these particles can be useful for elimination of parasite.
Surely this study was performed as preliminary work and
further studies on the drug are needed.
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